Innovating Works

RUPTURE

Financiado
Selenium Containing Rupturing Dendritic Prodrugs for Therapeutic Applications
Elevated rates of reactive oxygen species (ROS) have been detected in almost all cancers, where they promote many aspects of tumour development and progression. The radical generated, the location, as well as the local concentrati... Elevated rates of reactive oxygen species (ROS) have been detected in almost all cancers, where they promote many aspects of tumour development and progression. The radical generated, the location, as well as the local concentration, are essential for the cellular functions of ROS in cancer. Among redox modulating compounds, selenium derivatives have gained substantial attention due to their promising chemotherapeutic potential, which result from selenium’s ability to act as a pro-oxidant at high dosage. This proposal is intended to develop novel therapeutic agents based on selenium-containing dendrimers, which act as precision carriers with unparalleled structural perfection. These agents, with a plethora of internally queued selenium-selenium bridges will be activated upon the rupturing of the dendritic carriers by external stimuli. It is herein envisioned that RUPTURE can rise to the challenge, acting as cutting-edge prodrugs that will fine-tune intracellular ROS signalling to effectively deprive cells of ROS-induced tumour-promoting events, thereby tipping the balance to ROS-induced apoptotic signalling. ver más
31/01/2025
KTH
207K€
Perfil tecnológico estimado
Duración del proyecto: 30 meses Fecha Inicio: 2022-07-06
Fecha Fin: 2025-01-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-07-06
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021
Cerrada hace 3 años
Presupuesto El presupuesto total del proyecto asciende a 207K€
Líder del proyecto
KUNGLIGA TEKNISKA HOEGSKOLAN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5